Data as of Apr 17
| -0.50 / -2.68%|
The 8 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 41.50, with a high estimate of 65.00 and a low estimate of 28.00. The median estimate represents a +128.65% increase from the last price of 18.15.
The current consensus among 8 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.